Journal
CLIMACTERIC
Volume 15, Issue 3, Pages 263-266Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/13697137.2012.659975
Keywords
WOMEN'S HEALTH INITIATIVE STUDY; HORMONE REPLACEMENT THERAPY; PREVENTION OF OSTEOPOROSIS-RELATED FRACTURES
Categories
Funding
- Eli Lilly
- Janssen-Cilag
- Novo Nordisk
- Organon
- Schering
- Shire
- Solvay
- Wyeth
- Wellcome Trust
- UK Medical Research Council
Ask authors/readers for more resources
The Women's Health Initiative (WHI) randomized, controlled trial was the first study to prove that hormone replacement therapy (HRT) reduces the incidence of all osteoporosis-related fractures in postmenopausal women, even those at low risk of fracture. The study authors concluded that the bone-friendly aspect of HRT was limited in clinical practice as possible adverse effects outweighed possible benefit. On the strength of these publications, regulatory authorities downgraded the use of HRT for the prevention of fracture to second-line therapy. This article examines the original and subsequent evidence presented by the WHI study and concludes that the restrictions placed on HRT as a bone-specific drug by regulatory bodies have not withstood the test of time and are not supported by the data of the WHI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available